Sjogrens Syndrome Measured by Ultrasound

Arthritis & Rheumatism Associates, P.C.20 enrolled

Overview

Ultrasound study focused on salivary gland outcomes in Sjogren's subjects

A 32 week ultrasound study for subject diagnosed with Sjogren's Syndrome. Subjects will receive Orencia (Abatacept) as intervention therapy during this trial.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

SINGLE

Enrollment

Conditions

Sjogren's Syndrome

Interventions

OrenciaBIOLOGICAL

FDA approved biologic

PlaceboOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects diagnosed with Sjogren's Syndrome Exclusion Criteria: * Subjects previously diagnosed with Sarcoidsis * Subjects with positive for Hepatitis B, Hepatitis C, HIV * Subjects diagnosed with Cancer within 5 years of screening

Locations (1)

The Center for Rheumatology and Bone Research a division of Arthritis and Rheumatism Associates, P.C.

Wheaton, Maryland, United States

Outcomes

Primary Outcomes

Salivary gland changes

Salivary gland changes detected by ultrasound imaging with elastography

Time frame: 32 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.